Precursor Immunotherapy to Prevent Squamous Cell Carcinoma
Researchers evaluated whether treatment with calcipotriol plus 5-fluorouracil aided in reducing the risk of squamous cell carcinoma.
CONCLUSIONS: We developed a mouse model system to investigate a novel combinatory approach that illuminates a clinical path hypothesis for combining ICB with DNA damage-inducing therapies in the treatment of LSCC. PMID: 32209571 [PubMed - as supplied by publisher]
Authors: Liang MQ, Yu FQ, Chen C Abstract Immunotherapy using antibodies blocking the programmed cell death 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway has achieved great success in preclinical models and the clinical treatment of esophageal squamous cell carcinoma (ESCC). The c-Myc proto-oncogene helps prevent immune cells from attacking tumor cells by inducing PD-L1 expression. However, the underlying mechanisms of c-Myc and PD-L1 in ESCC remain unclear, and a thorough understanding of this regulation would allow the development of new approaches to enhance antitumor immunity. In the present study, th...
Although checkpoint blockades have become widely used, the immunological impact in cancer patients, especially those with oral cavity squamous cell carcinoma (OCSCC), has not been well studied.
SCCHNs are a complex and difficult-to-treat group of aggressive cancers. Surgery and radiotherapy remain the primary treatments for locoregional SCCHN; however, they are associated with significant morbidity and high recurrence rates. Although immune checkpoint inhibitors such as the anti-PD-1 antibody nivolumab are active in SCCHN, strategies to improve response rate and durability are needed. The development of more effective therapies is hindered by the immunosuppressive nature of these tumors.
Immunosuppressive myeloid cells activated in the tumor microenvironment (TME) are a critical limitation to the efficacy of immune checkpoint inhibitors (ICIs) in patients with head and neck squamous cell carcinoma (HNSCC). In preclinical models, antibody blockade of Semaphorin 4D (SEMA4D, CD100) reduced function and recruitment of immunosuppressive myeloid cells, while simultaneously restoring the ability of dendritic cells and cytotoxic T cells to infiltrate the TME. Importantly, this coordinated shift from immunosuppression to tumoricidal activity complemented effects of other immunotherapies in syngeneic tumor models, w...
Efficient use of nivolumab in recurrent/metastatic head and neck squamous cell carcinoma (r/mHNSCC) has been limited by the lack of a definitive predictive biomarker. We aimed to investigate the association between pretreatment neutrophil-to-lymphocyte ratio (NLR) and outcome of patients with r/mHNSCC treated with nivolumab.
T cell-mediated anti-tumor immune responses are gated in part by the relative abundance of cytotoxic T cells (Teffs) and regulatory (Tregs) in the tumor microenvironment (TME) whereby Treg may impair the efficacy of Teffs. Tregs can affect Teff function by direct cell-to-cell contact or by secretion of soluble mediators, consistent with the hypothesis that proximity of Tregs to Teff within tumor tissues may have prognostic significance. Here we used a novel chromogenic multiplex assay to investigate the spatial relationship of these functionally diverse T cell subsets in HPV positive and HPV negative head and neck squamous...
We examined treatment patterns and estimated real-world time on treatment (rwToT) with IO and non-IO based therapies post-PbC in patients with R/M HNSCC.
We report a series of patients with advanced head and neck cSCC treated with PD-1/PD-L1 blockade as first line systemic therapy.
Immune checkpoint inhibitors (ICIs) alone or with chemotherapy (CT) is a new standard of care in first-line recurrent, metastatic squamous cell carcinoma of the head and neck (SCCHN). With the growing use of ICIs in this setting, response rates to second-line CT are now being explored. We investigated whether prior ICI therapy associated with more favorable outcomes for SCCHN patients on CT, as ICIs may produce lasting immunomodulation that may influence subsequent CT benefit.